Last year, the prescription market for asthma medications containing the ‘budesonide’ ingredient expanded to its largest size ever. There have been significant demands for the treatment due to the circumstances surrounding the pandemic and endemic. At the end of last year, the drug pricing increase led to manufacturing and the prescription market expansion. Raising drug prices during shortages yielded a virtuous cycle of resolving the imbalance between supply and demand.

According to UBIST, a pharmaceutical market research agency, on the 14th, outpatient prescription sales of asthma medications with a single component of budesonide totaled 9.9 billion won last year, representing an increase of 39.1% com